| scholarly article | Q13442814 |
| P50 | author | John Christodoulou | Q42753915 |
| Abdel A. Belaidi | Q58463859 | ||
| Guenter Schwarz | Q64153769 | ||
| Saikat Santra | Q75839846 | ||
| Terry G J Derks | Q79762072 | ||
| P2093 | author name string | Elisabeth Jameson | |
| Alex Veldman | |||
| Evangeline Wassmer | |||
| Bernd C Schwahn | |||
| Julia B Hennermann | |||
| Flora Y Wong | |||
| Kai König | |||
| Anne Vierzig | |||
| Mamta Vaidya | |||
| Tracy L McGregor | |||
| Esperanza Font-Montgomery | |||
| Francjan J Van Spronsen | |||
| Ilona Weis | |||
| José A Santamaria-Araujo | |||
| Stephen Bowhay | |||
| P2860 | cites work | Genomic structure and mutational spectrum of the bicistronic MOCS1 gene defective in molybdenum cofactor deficiency type A | Q22008723 |
| Human molybdopterin synthase gene: genomic structure and mutations in molybdenum cofactor deficiency type B | Q22008844 | ||
| Mutations in the molybdenum cofactor biosynthetic genesMOCS1, MOCS2, andGEPH | Q24302091 | ||
| Ten novel mutations in the molybdenum cofactor genes MOCS1 and MOCS2 and in vitro characterization of a MOCS2 mutation that abolishes the binding ability of molybdopterin synthase | Q24307832 | ||
| Molybdenum cofactor biosynthesis and deficiency | Q33991147 | ||
| Molybdenum cofactors, enzymes and pathways | Q34018919 | ||
| The tetrahydropyranopterin structure of the sulfur-free and metal-free molybdenum cofactor precursor | Q34294783 | ||
| Rescue of lethal molybdenum cofactor deficiency by a biosynthetic precursor from Escherichia coli | Q34317217 | ||
| Molybdenum cofactor deficiency: clinical features in a Turkish patient | Q34589252 | ||
| Molybdenum cofactor deficiency: Mutations in GPHN, MOCS1, and MOCS2 | Q37804739 | ||
| Prenatal brain disruption in molybdenum cofactor deficiency | Q41935800 | ||
| Molybdenum cofactor deficiency: a new HPLC method for fast quantification of s-sulfocysteine in urine and serum | Q42097491 | ||
| Defective molybdopterin biosynthesis: clinical heterogeneity associated with molybdenum cofactor deficiency | Q42274382 | ||
| Chronological changes of the amplitude-integrated EEG in a neonate with molybdenum cofactor deficiency | Q42576777 | ||
| Successful treatment of molybdenum cofactor deficiency type A with cPMP. | Q43102443 | ||
| Molybdenum cofactor deficiency associated with Dandy-Walker complex | Q43807530 | ||
| Clinical neuroimaging features and outcome in molybdenum cofactor deficiency | Q48906574 | ||
| Timing of cerebral developmental disruption in molybdenum cofactor deficiency. | Q49027698 | ||
| Favorable outcome in a newborn with molybdenum cofactor type A deficiency treated with cPMP. | Q54023912 | ||
| Structure and stability of the molybdenum cofactor intermediate cyclic pyranopterin monophosphate | Q84855093 | ||
| P433 | issue | 10007 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | molybdenum cofactor deficiency | Q1621463 |
| molybdenum cofactor deficiency type A | Q50349830 | ||
| P304 | page(s) | 1955-1963 | |
| P577 | publication date | 2015-09-03 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Efficacy and safety of cyclic pyranopterin monophosphate substitution in severe molybdenum cofactor deficiency type A: a prospective cohort study | |
| P478 | volume | 386 |
| Q90054945 | A Scoping Review of Inborn Errors of Metabolism Causing Progressive Intellectual and Neurologic Deterioration (PIND) |
| Q41814416 | Chaperones in maturation of molybdoenzymes: Why specific is better than general? |
| Q47623373 | Critical appraisal of genotype assessment in molybdenum cofactor deficiency |
| Q27307124 | Development, implementation and evaluation of an evidence-based program for introduction of new health technologies and clinical practices in a local healthcare setting. |
| Q90287215 | EEG Monitoring of the Epileptic Newborn |
| Q93064093 | ETHE1 and MOCS1 deficiencies: Disruption of mitochondrial bioenergetics, dynamics, redox homeostasis and endoplasmic reticulum-mitochondria crosstalk in patient fibroblasts |
| Q39411002 | Inborn Errors of Metabolism and Epilepsy: Current Understanding, Diagnosis, and Treatment Approaches |
| Q41918146 | Isolated sulfite oxidase deficiency |
| Q37194386 | Molybdenum cofactor and isolated sulphite oxidase deficiencies: Clinical and molecular spectrum among Egyptian patients |
| Q38664978 | Molybdenum cofactor deficiency |
| Q89516649 | Mortality in a neonate with molybdenum cofactor deficiency illustrates the need for a comprehensive rapid precision medicine system |
| Q48772823 | Mouse model for molybdenum cofactor deficiency type B recapitulates the phenotype observed in molybdenum cofactor deficient patients |
| Q48123908 | Radical Breakthroughs in Natural Product and Cofactor Biosynthesis. |
| Q50901686 | Recent Advances in Neonatal Seizures. |
| Q64084923 | S-Sulfocysteine Induces Seizure-Like Behaviors in Zebrafish |
| Q47438228 | S-sulfocysteine/NMDA receptor-dependent signaling underlies neurodegeneration in molybdenum cofactor deficiency. |
| Q60944423 | Severe cystic degeneration and intractable seizures in a newborn with molybdenum cofactor deficiency type B |
| Q29147383 | Simultaneous impairment of neuronal and metabolic function of mutated gephyrin in a patient with epileptic encephalopathy |
| Q90265058 | The Role of Oxidative Stress and Bioenergetic Dysfunction in Sulfite Oxidase Deficiency: Insights from Animal Models |
| Q88537491 | The functional principle of eukaryotic molybdenum insertases |
| Q48390229 | Treatable mitochondrial diseases: cofactor metabolism and beyond |
| Q64049101 | Treatments for rare diseases: molybdenum cofactor deficiency |
| Q36865263 | Utility of whole exome sequencing for the early diagnosis of pediatric-onset cerebellar atrophy associated with developmental delay in an inbred population |